Akur8 Teams up With Pet Health Unicorn Bought By Many / ManyPets
Akur8 is pleased to announce the collaboration with pet health and insurance company Bought By Many to help boost the insurtech’s pricing capabilities. Through the partnership, Akur8 reinforces its presence in the UK, and further expands its area of expertise with a new line of business: pet health and insurance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220215005001/en/
Specifically developed for insurers, Akur8’s solution enhances pricing processes by automating risk modeling, using Transparent Artificial Intelligence proprietary technology. Core benefits for insurers include increased predictive performance and speed-to-accuracy for higher market reactivity and immediate business impact, while maintaining full transparency and control on the models created.
Since launching exclusively into pet insurance in the UK in 2017, Bought By Many has quickly become a fintech success story. The company expanded into the Swedish market in 2019 and earlier this year crossed the Atlantic to launch a state-by-state roll out in the US, both under the ManyPets brand. The group now insures half a million pets globally. In June 2021, the company gained unicorn status after securing a valuation of over $2bn following a $350m Series D funding round through its holding company Many Group. The investment has helped support Bought By Many’s global expansion and drive product development beyond its market-leading insurance offer.
Choosing Akur8’s best-in-class solution aligns with Bought By Many’s vision of making the world a better place for pets and will provide Bought By Many with enhanced pricing capabilities, including exceptionally fast and transparent automated modelling.
“Bought By Many is our first customer specialised in pet insurance, and we are delighted to announce this collaboration! Akur8 is honoured to support Bought By Many in its fast and impressive global development. This new alliance reflects Bought By Many's dedication to innovation in technology and service as well as transparency”, said Samuel Falmagne, CEO at Akur8.
“We are thrilled to add pet insurance as a new line of business in our portfolio, and to strengthen our position in the UK insurance market. As an exponentially growing insurer, Bought By Many is a great reference and we are proud to be working with them”, stated Brune de Linares, Chief of Sales at Akur8.
“We are continuing to revolutionise how owners access pet health services, products and advice. This means improving all stages of the pet ownership journey including pricing. Working with Akur8 and a new pricing solution will help us further improve our time-to-market and to deliver an even more outstanding customer experience as we continue to grow”, commented Charlotte Halkett, Chief Commercial Officer at Bought By Many.
“We are very pleased with Akur8’s performance. This solution will allow us to improve our modelling performance and to boost our speed-to-market, which is key to fuel our ambitious growth plans”, addedCharlotte Ball, Pricing Lead at Bought By Many.
About Akur8
Akur8 is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds.
Meet Bought By Many & ManyPets.
UK | SWEDEN | USA
We’re making the world a better place for pets and their parents with award-winning pet insurance and access to pet health and wellness services. We're reaching pet parents around the world, and now look after half a million pets globally. There’s a reason pet owners voted us Pet Insurance Provider Of The Year 2021. Actually, there are a few reasons. We offer the most comprehensive pet insurance policy in the UK with up to £15,000 of annual vet fee cover that resets every year plus we include cover for dental illness as standard. We help pet parents take care of all aspects of their pet’s health - for happier, healthier pets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005001/en/
Contact information
Media
For Akur8
Anne-Laure Klein
+33 (0)6 63 79 44 74
anne-laure.klein@akur8.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom